 NEW YORK, May 24, 2021 PRNewswire -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Strongbridge Biopharma plc Strongbridge or the Company NASDAQ: SBBP in connection with the Companys proposed merger with Xeris Pharmaceuticals, Inc. Xeris NASDAQ: XERS. Under the terms of the merger agreement, Strongbridge shareholders will receive 0.7840 shares of Xeris common stock for each share of Strongbridge common stock that they own, representing implied per-share merger consideration of approximately 2.72 based upon Xeris May 21, 2021 closing price of 3.47. 